In this episode of the Oncology Brothers podcast, we delved into the highlights from ASCO 2024, focusing on key studies in lung cancer. Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health, joined us to discuss the latest findings.
Key Points: 
- LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation.
- MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations.
- CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer.
- PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib
- ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer.
Overall, the episode emphasized the importance of precision medicine, the evolving landscape of treatment options in lung cancer, and the significance of multidisciplinary and patient-centered approaches in oncology practice.
Stay tuned for more highlights from ASCO 2024 across different cancer types in upcoming episodes. Thank you for listening to the Oncology Brothers podcast.